FDA Approves Genentech’s Evrysdi Tablet for SMA Treatment
The FDA has approved Genentech’s Evrysdi tablet, offering a more convenient option for SMA patients.
In a major advancement for spinal muscular atrophy (SMA) treatment, the FDA has approved a tablet form of Evrysdi® (risdiplam), Genentech announced today. This new option offers the same proven efficacy as the original oral solution but with added convenience, allowing patients to take the tablet whole or dissolve it in water. Designed for individuals aged two and older who weigh at least 44 pounds, the tablet provides a non-invasive, disease-modifying treatment that simplifies daily SMA management.
Experts emphasize the importance of this approval for patients and caregivers, as it makes treatment more accessible for those balancing work, travel, and daily routines. Kenneth Hobby, President of Cure SMA, praised the tablet’s ease of use, highlighting its impact on improving quality of life. The Evrysdi tablet is expected to be available in the coming weeks, reinforcing Genentech’s commitment to advancing SMA care in collaboration with the SMA Foundation and PTC Therapeutics.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
More from Pharma News
All stories →
IDEAYA Biosciences Achieves 17.4-Month Median OS with IDE849 ADC in Relapsed SCLC
FDA Issues Twelve Biologics Guidance Documents Covering Container Closure, Blood Manufacturing, and Biosimilars
Discussion